Inhibiting the development of the YAP/TAZ-TEAD complex with drugs such as verteporfin has demonstrated potential in preclinical models, indicating that enhancing the Hippo signaling pathway can be used as an anti-tumor strategy [105]. Here, YAP1 is linked to neoplasm.